New York, Jan 13, 2026, 14:49 EST — Regular session
- Shares of GeneDx slipped roughly 9% in afternoon trading following the company’s release of its 2026 revenue forecast.
- Management forecasted 2026 revenue between $540 million and $555 million, anticipating a positive adjusted net income.
- Investors are eyeing the company’s presentation at the J.P. Morgan Healthcare Conference on Jan. 14, with the full results due Feb. 23.
Shares of GeneDx Holdings Corp dropped roughly 8.7% to $108.90 Tuesday afternoon, continuing their slide after the genetic testing firm revealed its 2026 revenue forecast the previous day.
The drop is significant since GeneDx is now viewed as a high-expectations play: investors are swift to punish results that merely meet forecasts instead of beating them, particularly with a packed schedule of healthcare investor events coming up.
GeneDx submitted its outlook and preliminary, unaudited 2025 numbers in an 8-K filing on Monday. Investors often treat this kind of update as an early indicator before the full earnings release.
GeneDx laid out projections for full-year 2025 revenue at roughly $427 million in a deck for the J.P. Morgan Healthcare Conference, with Q4 revenue expected near $121 million. The company reported 97,271 exome and genome test results for the full year and ended with about $172 million in cash.
The company projects revenue between $540 million and $555 million for 2026, with exome and genome sales expected to climb 33% to 35%. It also anticipates an adjusted gross margin of at least 70% and positive adjusted net income, a non-GAAP metric that excludes certain items.
CEO Katherine Stueland said the company “delivered on our commitment to high growth and profitability” in 2025. CFO Kevin Feeley highlighted accelerating quarterly volume growth and added the company is “operating from a position of financial strength” as it heads into 2026. https://www.sec.gov/Archives/edgar/data/1818331/000181833126000005/preliminary2025resultspres.htm
GeneDx offers genetic tests that analyze either the exome — the protein-coding portion of DNA — or the entire genome. These tests mainly aid in diagnosing rare diseases. Growth in test volume is closely monitored as a key indicator of how quickly the company is expanding beyond specialist care.
Management’s next big moment comes Wednesday at the J.P. Morgan Healthcare Conference in San Francisco, where investors expect fresh insights on the 2026 forecast and early-year demand trends.
The conference takes place Jan. 12-15 and frequently serves as an early benchmark for healthcare stocks, particularly for firms looking to recalibrate expectations after releasing initial guidance.
TD Cowen analyst Dan Brennan noted the stock slipped following a preannouncement that was “in line,” a result that might underwhelm investors used to a streak of stronger quarterly beats. https://www.investing.com/news/stock-market-news/genedx-stock-falls-after-2026-guidance-disappoints-investors-93CH-4442869
But the setup isn’t without risk. The company emphasized that the 2025 numbers are preliminary and unaudited. The 2026 forecast hinges on test demand and reimbursement trends staying steady as GeneDx moves into wider markets.
GeneDx plans to release its fourth-quarter and full-year results on Feb. 23 before markets open, followed by a conference call at 8:30 a.m. ET.
Related articles: Biotechnology
